Cytochrome p-450 cyp2c19 - Open Access .click

Results 1 to 10 of about 4,664 (90)

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics

Frontiers in Pharmacology, 2022
Clinical practice environments without in-house pharmacogenetic testing often rely on commercial laboratories, especially in the setting of pharmacogenetic testing intended to guide psychotropic use.
Christopher Blazy +3 more
doaj +1 more source

Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance

Journal of the Pakistan Medical Association, 2023
Objectives: To find out the prevalence of CYP2C19*2 genetic polymorphism in ischemic heart disease patients, and to determine its relation with clopidogrel resistance in different genotype groups. Method: The cross-sectional study was conducted from August 2015 to December 2019 at the Army Medical College, National University of Medical Sciences ...
Usman, Nawaz, Mudassar, Noor, Akbar, Waheed +2 more
openaire +2 more sources

Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping [PDF]

Journal of Stroke, 2017
Background and Purpose To compare the efficacy and safety of antiplatelet agents for the secondary prevention of ischemic stroke based on cytochrome P450 2C19 (CYP2C19) polymorphisms.
Sang Won Han +20 more
doaj +1 more source

Determination of CYP2C19 Polymorphism, Side Effects, and Medication Adherence in Patients Who have Utilized Selective Serotonin Reuptake Inhibitors

Psychiatry and Clinical Psychopharmacology, 2021
Objective: The aim of this study is to determine relationship of cytochrome P-450 2C19 (CYP2C19) enzymes polymorphism, side effects, and medication adherence in patients who have been diagnosed with major depression and have utilized selective serotonin
Semanur Deniz +8 more
doaj +1 more source

Antiplatelet therapy de-escalation in a patient after percutaneous coronary intervention with a high risk of bleeding

Российский кардиологический журнал, 2023
According to recommendations of ESC 2020-year, de-escalation of therapy with a P2Y12 receptor inhibitor (transition from prasugrel or ticagrelor to clopidogrel) It can be considered as an alternative strategy of dual antiplatelet therapy (DAPT) for ...
A. A. Kassymova +3 more
doaj +1 more source

Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel

Platelets, 2021
In the setting of coronary heart diseases (CHDs) on treatment with clopidogrel, ADP-induced platelet aggregation has been demonstrated with ischemic events.
Huaibin Wan +5 more
doaj +1 more source

The interactions between COVID-19 drugs and psychotropic agents

European Psychiatry, 2021
Coronavirus disease (COVID-19) is a systemic infection targeting multiple organs. Interstitial pneumonia is the landmark feature of this condition. Severe acute respiratory symptoms requiring intensive care support arises for about one out of twenty ...
C. Hiemke
doaj +1 more source

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention

BMC Pharmacology and Toxicology, 2020
Background Clopidogrel is an inactive prodrug, it catalyzed into its active form by Cytochrome 450 and Paraoxonase-1(PON-1). polymorphisms of genes encoding these enzymes will affect the efficacy of Clopidogrel.
Zhaowei Zhang, Mingxiao Chen, Long Zhang, Qiang Zhao +3 more
doaj +1 more source

Inhibitory Effect of Antituberculosis Drugs on Human Cytochrome P450-Mediated Activities

Journal of Pharmacological Sciences, 2004
The potential for drug-drug interactions mediated by the inhibition of cytochrome P-450 (CYP) were concerned during antituberculosis therapy. However, the information regarding human CYP inhibition by antituberculosis drugs is limited to isoniazid.
Yuki Nishimura +3 more
doaj +1 more source

Genetic risk factors of cytolysis syndrome in the treatment of recrudescence of chronic cardiovascular diseases

Российский кардиологический журнал, 2018
Aim. To assess the clinical, biochemical, and genetic risk factors for the development of hepatocyte cytolysis syndrome in patients with a combination of fatty liver disease and recrudescence of chronic cardiovascular pathology.Material and methods.
N. V. Kokh +4 more
doaj +1 more source

clopidogrel
pharmacology
therapeutics